Similarities, differences and agonisms of pleiotropic effects of statins and omega-3 fatty acids;Similitudes, diferencias y agonismos en los efectos pleiotrópicos de las estatinas y los ácidos grasos omega-3

Nutricion Hospitalaria

Volumn 25, Issue 6, 2010, Pages 889-909

  Villalobos, M E ^a   Sanchez Muniz F J ^a   Acin M T ^b   Vaquero, M P ^c   Higueras, F J ^a   Bastida, S ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c INSTITUTO DEL FRÍO CSIC   (Spain)

Author keywords

Antioxidant; Blood pressure; Endothelial function; Inflammation; Insulin sensitivity; n 3 PUFA; Pleiotropic effects; Statins; Thrombosis

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID;

ANIMAL; BODY WEIGHT; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; INSULIN RESISTANCE; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BODY WEIGHT; CARDIOVASCULAR DISEASES; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FATTY ACIDS, OMEGA-3; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE;

EID: 78649618892     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2010.25.6.4819     Document Type: Article

References (158)

1. Vaquero MP, Jiménez-Redondo S, Prats Olivan P, Higueras FJ, Bastida S y Sánchez-Muniz FJ. Major diet-drug interactions affecting the kinetics characteristics and hypolipidaemic properties of statins. Nutr Hosp 2010; 25: 193-206.
2. Flénez J, Freijanes J. Fármacos hipolipoproteinemiantes. Control de la obesidad. En: Flénez J, Armijo J, Mediavilla A, eds. Farmacología Humana, Masson pp 1073-92. Barcelona, 2008.
3. Davidson MH. Safety profiles for HMG-CoA reductase inhibitors. Drugs 2001; 61: 1917-1926.
4. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: 1-5.
5. Karlezi A, Mata Pariente N, Mata Lénez P. Control de las dislipemias en la práctica clínica. Rev Esp Cardiol 2007; 6: 24-35.
6. Aguiar-Souto P, Cabanas-Grandío P, Gonzénez-Juanatey JR. La enfermedad polivascular aterotrombótica: un enemigo común y distintos frentes. Rev Esp Cardiol 2009; 9: 4-10.
7. Fernández de Bobadilla J, Moreno C, Fernández R, Marténez A, Sánchez-Maestre C, Ezpeleta-Echevarri D. Efecto del tratamiento intensivo con atorvastatina frente a dosis estándar de estatinas en el riesgo de ictus de pacientes con enfermedad coronaria previa. Metaanótisis de cinco ensayos aleatorizados con 25.709 pacientes Rev Neurol 2009; 48: 561-5.
8. Rawlings R, Nohria A, Liu P, Donnelly J, Creager M, Ganz P et al. Comparison of effects of Rosuvastatin (10 mg) versus Atorvastatin (40 mg) on Rho kinase activity in Caucasian men with a previous atherosclerotic event. Am J Cardiol 2009; 103: 437-41.
9. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y et al. on behalf of the MUSASHI-AMI Investigators. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction subanalysis of MUSASHI-AMI. Circ J 2007; 71: 1348-53.
10. Sánchez-Muniz FJ, Bastida S, Gutiérrez-García O, Carbajal A. Olive oil-diet improves the simvastatin effects with respect to sunflower oil-diet in men with increased cardiovascular risk. A preliminary study. Nutr Hosp 2009; 24: 333-9.
11. Sánchez-Muniz FJ, Nus M. Importancia de la interacción dietagenótica en la prevención cardiovascular. En: Vaquero P (coordinador). Instituto Tomás Pascual Sanz y CSIC. EDIMSA Genótica, Nutrición y Enfermedad. Madrid: Editores Móticos, S.A., 2008; pp. 125-44.
12. Nissen S, Tuzcu M, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis. JAMA 2004; 291: 1071-80.
13. Stockins B. Efectos pleiotróticos de las estatinas. Rev Chil Cardiol 2009; 28: 198-201.
14. Hadi HA, Mahmeed WA, Suwaidi JA, Ellahham S. Pleiotropic effects of statins in atrial fibrillation patients: the evidence. Vasc Health Risk Manag 2009; 5: 533-51.
15. Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset diabetes: a metaanalysis of randomized controlled trials. Curr Med Res Opin 2008; 24: 1359-62.
16. Baker W, Talati R, White C, Coleman C. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010; 87: 98-107.
17. King DE, Mainous AG 3rd, Egab BM, Player M, Geesey ME. Use of statins and blood pressure. Am J Hypertens 2007; 20: 937-41.
18. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIONorth America: a randomized controlled trial. JAMA 2006; 295: 761-75.
19. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO- Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO- Europe study. Lancet 2005; 365: 1389-97. (Pubitemid 40523733)
20. Ruiz A. Aterosclerosis, inflamación e intervenciones, prevención, estabilización y regresión de placa. Rev Peruana Cardiol 2007; 33: 87-95.
21. Harris W. Omega-6 and omega-3 fatty acids: partners in prevention. Curr Opin Clin Nutr Metab Care 2010; 13: 125-9.
22. Carrero JJ, Martín-Bautista E, BaróL, FonolláJ, Jiménez J, Boza JJ, et al. Efectos cardiovasculares de los ótidos grasos omega-3 y alternativas para incrementar su ingesta. Nutr Hosp 2005; 20: 63-9.
23. London B, Albert C, Anderson ME, Giles WR, Van Wgoner DR, Balk E et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of dietary supplements omega-3 fatty acids and their role in cardiac arrhytmogenesis Workshop. Circulation 2007; 116: 320-35.
24. Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyunsaturated fatty acids as antioxidants. Pharmacol Res 2008; 57: 451-5.
25. Colussi G, Catena C, Baroselli S, Nadalini E, Lapenna R, Chiuch A, et al. Omega-3 fatty acids: from biochemistry to their clinical use in the prevention of cardiovascular disease. Recent Pat Cardiovasc Drug Discov 2007; 2: 13-21.
26. GISSI-Prevenzione. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nellótinfarto miocardico. Lancet 1999; 354: 447-55.
27. Marténez-Gonzénez J, Badimon L. Estatinas y ótidos grasos omega-3. Disminución de la mortalidad cardiovascular. Rev Esp Cardiol Supl 2006; 6: 20-30.
28. Mataix-VerdúJ, Vidal Carou MC. Alimentos ricos en lótidos. En: Mataix-VerdúJ. Nutrición y Alimentación Humana. Ergon, pp. 407-29. Madrid, 2009.
29. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in North Western Greenland. Am J Clin Nutr 1980; 33: 2657-61.
30. Rideout TC, Harding SV, Mariangeli CP, Jones PJ. Combination drug-diet therapies for dyslipidemia. Transl Res 2010; 155: 220-7.
31. Santa Olalla M de, Sánchez-Muniz FJ, Vaquero MP. N-3 fatty acids and insulin resistance. Nutr Hosp 2009; 24: 113-27.
32. Lichtenstein AH, Ausman LM, Carrasco W, Jenner JL, Ordovas JM, Schaefer EJ. Hypercholesterolemic effect of dietary cholesterol in diets enriched in polyunsaturated and saturated fat. Dietary cholesterol, fat saturation, and plasma lipids. Arterioscler Thromb 1994; 14: 168-75.
33. García-Rís A, Meneses ME, Pénez-Marténez P, Pénez-Jiménez F. Omega-3 and cardiovascular disease: beyond the risk factors. Nutr Clin Diet Hosp 2009; 29: 4-16.
34. Mori, TA. Omega-3 fatty acids and blood pressure. Cell Mol Biol (Noisy-le-grand). 2010; 56: 83-92.
35. Denicola A, Batthyany C, Lissi E, Freeman, BA, Rubbo H, Radi R. Diffusion of nitric oxide into low density lipoprotein. J Biol Chem 2002; 277: 932-6.
36. Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR et al. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure. Hypertension 2007; 50: 313-9.
37. Beermann C, Jelinek J, Reinecker T, Hauenschild A, Boehm G, Klá HU. Short term effects of dietary medium-chain fatty acids and n-3 long-chain polyunsaturated fatty acids on the fat metabolism of healthy volunteers. Lipids Health Dis 2003;17 (2): 10.
38. Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart dsease. JAMA 2010; 303: 250-7.
39. Sánchez Vallejo G. ¿Quéson los ótidos grasos omega-3? Guías Colombianas de Cardiolog? ¿Quédebe saber un mótico sobre los ótidos grasos omega-3? Sociedad Colombiana de Cardiolog? y Cirug? Cardiovascular. Asociación Colombiana de Medicina Interna Federación Diabetolótica Colombiana. Rev Colomb Cardiol 2009; 16 (supl. 1): 5-6.
40. Nus M, Ruperto M, Sánchez-Muniz FJ. Frutos secos y riesgo cardio y cerebrovascular. Una perspectiva española. Arch Latinoamer Nutr 2004; 54: 137-48.
41. Valenzuela A, Nieto MS. Ácido docosahexaenoico (HA) en el desarrollo fetal y en la nutrición materno-infantil. Rev Med Chile 2001; 129: 1203-11.
42. Farmer JA. Nicotinic acid: a new look at an old drug. Crr Atheroscler Rep 2009; 11: 87-92.
43. Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr 2008; 27: 659-66.
44. FAO/WHO. Preparation and use of food-based dietary guidelines. Report of a Joint FAO/WHO Consultation. Geneva, World Health Organization. 1998; (WHO Technical Report Series, No. 880).
45. FAO/WHO. Interim summary of conclusions and dietary recommendations on total fat and fatty acids. From the joint FAO/WHO Expert Consultation on fat and fatty acids in human nutrition. November 10-14, 2008, WHO HQ, Geneva.
46. Ros E. Guía para una alimentación cardiosaludable. Aporte de grasa. En: Sociedad española de Nutrición Comunitaria. Guías alimentarias para la población española. Recomendaciones para una dieta saludable. pp. 413-421, 2001.
47. Sánchez-Muniz FJ, Bastida S. Ácidos grasos omega-3 y protección cardiovascular. Consideraciones sobre su consumo y recomendaciones para la población española. Rev Nutr Práctica 1997; 1: 123-38.
48. Jan L Breslow. N-3 fatty acids and cardiovascular disease. Am J Clin Nutr. 2006; 83 (suppl.): 1477S-82S.
49. Rubio MA, Moreno C, Cabrerizo L. Guía para el tratamiento de las dislipidemias en el adulto: Adult Treatment Panel III (ATP III). Endocrinol Nutr 2004; 51: 254-65.
50. Nus M, Bastida S, Sánchez-Muniz FJ. Dietoterapia en la prevención de enfermedades cardiovasculares. En:Departamento de Nutrición y Bromatología I (Nutrición). Facultad de Farmacia. Universidad Complutense. Dietótica. másulo 5, Experto en Nutrición y Planificación Dietótica. Departamento de Nutrición y Bromatología I (Nutrición). Facultad de Farmacia. Universidad Complutense y COINSA (editores). tínulo Propio de la Universidad Complutense de Madrid, 2007.
51. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999; 340: 115-26.
52. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200:135-40.
53. Díaz E, Galgani J. Aspectos metabóticos y dietarios involucrados en la etiología de la obesidad en mujeres chilenas. Rev Med Chil 1999; 127: 1126-35.
54. Romás C, Almendro M, Valenzuela LF, Recio A, Cruz JM, Lénez V. Efectos pleitróticos de las estatinas. Rev Esp Cardiol 2003; 3 (suppl. C): 14-24.
55. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 1050: 1064.
56. King DE, Mainous AG, Egan BM, Player M, Geesey ME. Use of statins and blood pressure. Am J Hypertens 2007; 20: 937-41.
57. Higueras Lénez FJ. Atención Farmacíatica en pacientes con consumo preferente de carne o pescado y en tratamiento de pravastatina y simvastatina. Tesis Doctoral. Facultad de Farmacia. Universidad Complutense de Madrid, 2010.
58. Connor W, Lin D, Colvis C. Differential mobilization of fatty acids from adipose tissue. J Lipid Res 1996; 37: 290-8.
59. Sáyago-Ayerdi, SG, Vaquero P, Schultz-Moreira A, Bastida S, Sánchez-Muniz, FJ. Utilidad y controversia del consumo de ótidos grasos de cadena media sobre el metabolismo lipoproteico y obesidad. Nutr Hosp 2008; 23: 265-76.
60. Raclott T, Groscolas R. Diferential mobilization of white adipose tissue fatty acids according to chain length, unsaturation, and positional isomerism. J Lipid Res 1993; 34: 1515-26.
61. Lin D, Conner W. Are the n-3 fatty acids from dietary fish oil deposited in the TAG stores of adipose tissue? Am J Clin Nutr 1990; 51: 535-9.
62. Sánchez-Muniz FJ, Bastida S. Nutrición y lótidos. Biodisponibilidad de ótidos grasos. Rev Nutr Práctica 2000; 4: 48-64.
63. Mataix J, Gil A. Los ótidos grasos poliinsaturados omega-3 y monoinsaturados tipo oleico y su papel en la salud. En: Mataix J, Gil A. Libro Blanco de los Omega-3. Instituto Omega-3. Fundación Puleva: Granada, 2002.
64. Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Vecka M et al. Omega-3 PUFA of marine origin limit dietinduced obesity in mice by reducing cellularity of adipose tissue. Lipids 2004; 39: 1177-86.
65. Domásguez Franco AJ, Pénez Caravante M, Jiménez Navarro MF, Galv? E. Prevención y tratamiento del síndrome coronario agudo. Rev Esp Cardiol 2006; (suppl. 6): 36G-45G.
66. Serra Lluch M, Iglesias Arteaga EA. Influencia de los niveles de colesterol sobre el metabolismo de la arginina y el estró oxidativo. Efectos del tratamiento con estatinas. Tesis Doctoral. Universidad de Valencia, 2008.
67. Mennickent S, Bravo M, Calvo C, Avello M. Efectos pleiotróticos de las estatinas. Rev Med Chile 2008; 136: 775-82.
68. Huacuja Álvarez F, Génez Duque M, Ortiz Vargas JC, Soberanes Veláquez B, Aróalo Moreno V, Morales Villegas E et al. Efecto de las estatinas más alládel colesterol. Rev Endocrinol Nutr 2006; 14: 73-88.
69. Ramos-Esquivel A. León-Cespedes C. Efectos no hipolipemiantes de las estatinas. Acta Med Costarricense 2007; 49: 182-9.
70. Echeverri D, Buitrago L, Montes FR. Efectos pleiotróticos de las estatinas. Caracteróticas farmacolóticas ótiles en la prevención, tratamiento y regresión de la enfermedad cardiovascular. Rev Col Cardiol 2005; 12: 103-12.
71. Unoki H, Fan J, Watanabe T. Low-density lipoproteins modulate endothelial cells to secrete endothelin-1 in a polarized patter: a study using a culture model system simulating arterial intima. Cell Tissue Res 1999; 295: 89-99.
72. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelialderived relaxing factors by oxidized lipoproteins. J Clin Invest 1992; 89: 10-8.
73. Hernández-Perera O, Pénez-Sala D, Navarro-Antolá J, Sánchez- Pascuala R, Hernández G, Díaz C et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.
74. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998; 97: 1129-35. (Pubitemid 28152885)
75. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-5A.
76. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
77. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000; 36: 617-21.
78. Génez-Doblas JJ, Jiménez-Navarro MF, García-Pinilla JM, Rodróuez-Bailá I, Robledo J, Cabrera F, et al. Influencia del tratamiento temprano con estatinas en la función endotelial tras el infarto de miocardio en pacientes con valores normales de colesterol. Estudio VAATOPE (VAlue of ATOrvastatin inPostinfarction Endothelium). Med Clin (Barc.) 2006; 126: 325-8.
79. Leeson CP, Mann A, Kattenhorn M, Deanfield JE, Lucas A, Muller DP. Relationship between circulating n-3 fatty acid concentrations and endothelial function in early adulthood. Eur Heart J 2002; 23: 216-22.
80. Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis 1997; 132: 131-8.
81. Alcaíno H, Castro P, Greig D, Verdejo H, Chiong M, García L et al. El tratamiento con atorvastatina reduce la actividad de xantina-oxidasa unida al endotelio en pacientes con insuficiencia cardánca crótica: ¿Un posible nuevo efecto pleiotrótico? Rev Chil Cardiol 2009; 28: 139-49.
82. Chen MF, Hsu HC, Lee YT. Short-term treatment with lowdose pravastatin attenuates oxidative susceptibility of low density lipoprotein in hypercholesterolemic patients. Cardiovasc Drugs Ther 1997; 11: 787-93.
83. Sumura K, Yasuhara K, Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, an oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 1999; 57: 697-703.
84. Vora DK, Fang ZT, Liva SM, Tyner TR, Parhami F, Watson AD, et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 1997; 80: 810-8.
85. Liu B, Sidiropoulos A, Zhao B, Dierichs R. Oxidized LDL damages endothelial cell monolayer and promotes thrombocyte adhesion. Am J Hematol 1998; 57: 341-3.
86. Canales A, Sánchez-Muniz FJ. Paraoxonasa, ¿algo más que una enzima? Med Clin (Barc.) 2003; 121: 537-48.
87. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-42.
88. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC inhibition. Proc Natl Acad Sci USA 2006; 103: 15184-9.
89. Serhan CN, Clish CB, Brannon J, Colgana SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med 2000; 192: 1197-204.
90. Canales A, BenedúJ, Nus M, Librelotto J, Sánchez-Montero JM, Sánchez-Muniz, FJ. Effect of walnut-enriched restructured meat in the antioxidant status of overweight/obese senior subjects with at least one extra CHD-risk factors. J Am Coll Nutr 2007; 26: 225-32.
91. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-20.
92. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Col Cardiol 2000; 35: 1-10.
93. Aikawa M, Rabkin E, Sugiyama S, Voglic S, Fukumot Y, Furukawa Y et al. An HMGCoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-83.
94. Hernández Madrid A. Proteína C reactiva y fibrilación auricular. Un viejo marcador en busca de un nuevo sitio. Rev Esp Cardiol 2006; 59: 94-8.
95. Gonzálvez M, Ruiz Ros JA, Pénez-Paredes M, Lozano ML, Giménez DM, Marténez-Corbalá F et al. Efecto de la administración precoz de pravastatina en los valores de Proteína C reactiva y de interleucina 6 en la fase aguda del infarto de miocardio con elevación del segmento ST. Rev Esp Cardiol 2004; 57: 916-23.
96. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512-5.
97. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of tatins therapy on C-reactive protein levels: The Pravastatin Inflammation/ CPR Evaluation (PRINCE) a randomized trial and cohort study. JAMA 2001; 286: 64-70.
98. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
99. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
100. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5.
101. Van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002; 165: 361-6.
102. Dimitrow PP, Jawien M. Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini Rev Med Chem 2009; 9: 1030-9.
103. Bellido C, Lénez-Miranda J, Blanco-Colio LM, Pénez- Marténez P, Muriana FJ, Martin-Ventura JL et al. Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor kappaB in peripheral blood mononuclear cells from healthy men. Am J Clin Nutr 2004; 80: 1487-91.
104. De Caterina R, Madonna R, Massaro M. Effects of omega-3 fatty acids on cytokines and adhesion molecules. Curr Atheroscler Rep 2004; 6: 485-91.
105. Schaefer MB, Wenzel A, Fischer T, Braun-Dullaeus RC, Renner F, Dietrich H et al. Fatty acids differentially influence phosphatidylinositol 3-kinase signal transduction in endothelial cells: impact on adhesion and apoptosis. Atherosclerosis 2008; 197: 630-7.
106. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002; 13 (suppl. 1): 1-6.
107. Espinosa R. Modificaciones de los lótidos sóticos, el fibrinéneno y otros parénetros hemostóticos por acción del ciprofibrato, en pacientes hiperlipidóticos con y sin Enfermedad Arterial Coronaria. Invest Clin 2006; 47: 35-48.
108. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287-94.
109. La Rosa JC, He J, Vupputuri S. Effect of statin on risk of coronary disease. A meta-analysis of randomised controlled trials. J Am Med Assoc 1999; 282: 2340-6.
110. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. J Am Med Assoc 1998; 279: 1643-50.
111. Mataix-VerdúJ, Raménez Hernandez JA, SoláAlberich R. Enfermedades del sistema circulatorio. En: Mataix-VerdúJ. Nutrición y Alimentación Humana. Ergon pp. 1469-1517, Madrid, 2009.
112. Lénez FarróA, Macaya C. Efectos antitrombóticos y antiinflamatorios de los ótidos grasos omega-3. Rev Esp Cardiol 2006; 6 (suppl. D): 31-7.
113. Swann PG, Venton DL, Le Breton GC. Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxaneA2/ prostaglandin H2 receptor in human platelets. FEBS Lett 1989; 30 (243): 244-6.
114. Vanschoonbeek K, Feijge MA, Paquay M, Rosing J, Saris W, Kluft C et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscl Thromb Vasc Biol 2004; 24: 1734-40.
115. Canales A, Bastida S, Librelotto J, Nus M, Sánchez-Muniz FJ, Benedi J. Platelet aggregation, eicosanoid production and thrombogenic ratio in individuals at high cardiovascular risk consuming meat enriched in walnut paste. A crossover, placebo-controlled study. Br J Nutr 2009; 102: 134-41.
116. Mataix-VerdúJ, Soriguer Escofet F. Diabetes Mellitus. En: Mataix-VerdúJ. Nutrición y Alimentación Humana: Ergon, pp. 1555-83, Madrid 2009.
117. Martín PM, Lecumberri E, Pascual y Alfonso L. Nutrición y síndrome metabótico. Rev Esp Salud Publica 2007; 81: 489-505.
118. Garaulet M, Pénez-Llamas F, Pénez-Ayala M, Marténez P, De Medina FS, Tebar FJ et al. Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterranean area. Relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr 2001; 74: 585-91.
119. Nugent C, Prins JB, Whitehead JP, Wentworth JM, Chatterjee VK, O'Rahilly S. Arachidonic acid stimulates glucose uptake in 3T3-L1 adipocytes by increasing GLUT1 and GLUT4 levels at the plasma membrane. Evidence for involvement of lipoxygenasemetabolites and peroxisome proliferator-activated receptor gamma. J Biol Chem 2001; 276: 9149-57.
120. Browning LM, Krebs JK, Moore CS, Mishra JD, O'Connell MA, Jebb SA. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 2007; 9: 70-80.
121. Nettleton JA, Katz R. N-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 2005; 105: 428-40.
122. Schraer CD, Mayer AM, Vogt AM, Naylor J, Brown TL, Hastie J et al. The Alaska Native diabetes program. Int J Circumpolar Health 2001; 60: 487-94.
123. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:2083-92.
124. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate ofatrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4.
125. Villegas FA. Prevención primaria en fibrilación auricular. Guías de diagnóstico y tratamiento de la fibrilación auricular. Rev Col Cardiol 2007; 14: 160-4.
126. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93: 780-2.
127. Chello M, Spadaccio C, Patti G, Lusini M, Barbato R, Goffredo C et al. Simvastatin reduces platelet endocardium adhesion in atrial fibrillation. Atherosclerosis 2008; 197: 588-95.
128. Kourliouros A, De Souza A, Roberts N, Marciniak A., Tsiouris A, Valencia O et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008; 85: 1515-20.
129. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetman PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989; 2: 757-61.
130. Brouwer IA, Zock PL, Camm AJ, B?ker D, Hauer RN, Wever EF et al.; SOFA Study Group. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial JAMA 2006; 295: 2613-9.
131. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005; 293:2884-91.
132. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104-9.
133. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
134. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490-1500.
135. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 2006; 12: 1623-35.
136. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension JAMA 2003; 290: 2945-51.
137. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40: 142-7.
138. Feldstein CA. Statins in hypertension: Are they a new class of antihypertensive agents? Am J Ther 2010; 17: 255-62.
139. O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howea LG, et al. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994; 3: 404-6.
140. Foss OP, Graff-Iversen S, Istad H, Soyland E, Tjeldflaat L, Graving B. Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention. Scand J Prim Health Care 1999; 17: 122-7.
141. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005; 19: 103-9.
142. Koh KK, Quon MJ, Han SH, Chung W-Jin, Ahn JY, Seo Y-H, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.
143. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6.
144. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-9.
145. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
146. Cicero AF, Derosa G, Di Gregori V, Bove M, Gaddi AV, Borghi C. Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens 2010; 32: 137-44.
147. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-57.
148. Jayasooriya AP, Begg DP, Chen N, Mathai ML, Sinclair AJ, Wilkinson- Berka J et al. Omega-3 polyunsaturated fatty acid supplementation reduces hypertension in TGR(mRen-2)27 rats. Prostaglandins Leukot Essent Fatty Acids 2008; 78: 67-72.
149. Bermejo J; Segovia J; Alfonso F. Resénenes de los ensayos
150. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008; 102: 429-33.
151. Nordú A, B?aa KH, Sandset PM, Hansen J, Nilsen H. Effect of ú-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 2000; 20: 259-65.
152. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol 2006; 98: 34i-8i.
153. Nordú A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost 2003; 1: 690-7.
154. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002; 48: 877-83.
155. Hong H, Xu ZM, Pang BS, Cui L, Wei Y, Guo WJ, et al. Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia. Chin Med Sci J 2004; 19: 145-9.
156. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-21.
157. Dolores Corella. Diet-gene interactions between dietary fat intake and common polymorphisms in determining lipid metabolism. Grasas y Aceites 2009; 60: 22-7.
158. British Nutrition Foundation. Unsaturated fatty acids, the thrombogenesis and fibrinolysis. En: The British Nutrition Foundation. Unsaturated fatty acids: nutritional and physiological significance. The report of the British Nutrition Foundation's Task Force. London: Chapman & Hall, 1992; pp. 92-113.